NWPF

News ArchivesRead News

Overexpression of alpha-synuclein can cause Parkinson's

Monday February 11, 2013

www.news-medical.net - Researchers at the University of California, San Diego School of Medicine say overexpression of a protein called alpha-synuclein appears to disrupt vital recycling processes in neurons, starting with the terminal extensions of neurons and working its way back to the cells' center, with the potential consequence of progressive degeneration and eventual cell death.

The findings, published in the February 6, 2013 issue of The Journal of Neuroscience, have major implications for more fully understanding the causes and mechanisms of Parkinson's disease (PD), a neurodegenerative movement disorder that affects an estimated one million Americans.

"This is an important new insight. I don't think anybody realized just how big a role alpha-synuclein played in managing the retrieval of worn-out proteins from synapses and the role of alterations in this process in development of PD," said principal investigator Mark H. Ellisman, PhD, professor of neurosciences and bioengineering and director of the National Center for Microscopy and Imaging Research (NCMIR), based at UC San Diego.

Parkinson's disease is characterized by the gradual destruction of select brain cells that produce dopamine, a neurotransmitter involved in regulating movement and emotion. Symptoms include increasing loss of muscle and movement control. While most cases are sporadic - that is, their causes are unknown - there are also inherited forms of PD linked to specific gene mutations and modifications.

The UC San Diego researchers, with colleagues at the University of Illinois, Urbana, focused upon one of those gene products: alpha-synuclein. Using a variety of leading-edge imaging technologies, including a new fluorescent tagging technique developed for electron microscopy by UC San Diego Nobel laureate Roger Tsien's lab and colleagues at NCMIR, the scientists created three-dimensional maps of alpha-synuclein distribution both in cultured neurons and in the neurons of mice engineered to over-express the human protein.

They found that excess levels of alpha-synuclein accumulated in the presynaptic terminal - part of the junction where axons and dendrites of brain cells meet to exchange chemical signals.

"The over-expression of alpha-synuclein caused hypertrophy in these terminals," said Daniela Boassa, PhD, a research scientist at NCMIR and the study's first author. "The terminals were enlarged, filled with structures we normally don't see."

Boassa said that as alpha-synuclein accumulates in the terminals, it appears to hinder normal degradation and recycling processes in neurons. This would progressively impair the release of neurotransmitters. In time, the neurons might simply stop functioning and die.

"Other studies have noted that PD is characterized by progressive loss of vesicle traffic, and neurotransmitter release," Boassa said. "Our study provides a structural and mechanistic explanation for why that happens."

Boassa said the findings shed greater light upon how PD is caused, at least in some heritable forms. Researchers plan to now probe more deeply into how the disease is propagated and how dysfunctional alpha-synuclein proteins spread from one neuron to another, hastening the advance of the disorder.

"The better we understand the mechanisms of PD, the easier it will be to develop clinical interventions," she said.

Source: University of California, San Diego School of Medicine

Recent News

Jul 24 - Parkinson's: Mutant gene interaction may pave the way for new treatments
Jul 22 - Boxing training used to fight against Parkinson's disease
Jul 17 - Stem cell treatment breakthrough could cure Parkinson’s patients
Jul 14 - Cancer drug shows early promise for Parkinson's disease
Jul 13 - Opinion: Dividing the Caregiving Responsibilities Between Siblings
Jul 12 - Researchers make advance in possible treatments for Gaucher, Parkinson’s diseases
Jul 11 - Parkinson’s Head Trauma Link Looks Even Stronger
Jul 7 - Penn students’ start-up XEED puts wearables to work against Parkinson’s disease
Jul 5 - Last Patient Enrolled in Pivotal Phase 3 Parkinson’s Disease Trial, Cynapsus Therapeutics Says
Jun 29 - Exoskeleton Could Quell the Tremors of Parkinson's Disease Patients at Crucial Moments
Jun 28 - Parkinson's disease: New protein discovery could fuel new treatments
Jun 27 - Study finds direct evidence linking Parkinson’s to autoimmune disease; 2 genes that are key regulators of immune system discovered
Jun 27 - Blocking key enzyme halts parkinson's disease symptoms in mice
Jun 23 - Parkinson's Research Might Benefit from Novel Discovery of Zinc Transport Protein Structure
Jun 23 - Parkinson's disease breakthrough 'could lead to cure'
Jun 20 - More American men diagnosed with Parkinson's
Jun 15 - First monkey genetically engineered to have Parkinson’s created
Jun 14 - Fighting Parkinson's in the lab
Jun 9 - A New Gene Has Been Linked to Parkinson's Disease
Jun 6 - A neurologist weighs in on Muhammad Ali's battle with Parkinson's disease